Product Code: ETC8846598 | Publication Date: Sep 2024 | Updated Date: Apr 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Drug manufacturers in the Philippines are focusing on developing neurodegenerative drugs that slow disease progression and improve patient quality of life. The increasing adoption of biosimilars and generics, along with regulatory support for drug development, is fostering market growth.
The increasing burden of neurodegenerative diseases and advancements in drug discovery are fueling the demand for neurodegenerative drugs in the Philippines. Pharmaceutical companies are investing in R&D to develop innovative therapies, including monoclonal antibodies and small-molecule drugs. Additionally, the rising focus on early intervention and preventive care supports market expansion.
The neurodegenerative drugs market faces obstacles in affordability and drug efficacy. Many existing drugs provide only symptomatic relief rather than halting disease progression, making them less attractive for long-term use. Additionally, high drug costs and a lack of generic alternatives limit accessibility for many patients.
The demand for neurodegenerative drugs in the Philippines is expected to rise as the population ages and neurological disorders become more prevalent. Investors can focus on developing targeted treatments for Alzheimer`s, Parkinsons, and multiple sclerosis. Companies working on drug repurposing, precision medicine, and neuroprotective compounds can find significant market potential.
Policies regulate neurodegenerative drugs to ensure patient safety and accessibility. Government initiatives aim to subsidize these medications for elderly patients and those with disabilities. Research funding is allocated to explore innovative drug therapies for neurodegenerative conditions.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Philippines Neurodegenerative Drugs Market Overview |
3.1 Philippines Country Macro Economic Indicators |
3.2 Philippines Neurodegenerative Drugs Market Revenues & Volume, 2021 & 2031F |
3.3 Philippines Neurodegenerative Drugs Market - Industry Life Cycle |
3.4 Philippines Neurodegenerative Drugs Market - Porter's Five Forces |
3.5 Philippines Neurodegenerative Drugs Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.6 Philippines Neurodegenerative Drugs Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.7 Philippines Neurodegenerative Drugs Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Philippines Neurodegenerative Drugs Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Philippines Neurodegenerative Drugs Market Trends |
6 Philippines Neurodegenerative Drugs Market, By Types |
6.1 Philippines Neurodegenerative Drugs Market, By Drug Class |
6.1.1 Overview and Analysis |
6.1.2 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Drug Class, 2021- 2031F |
6.1.3 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Dopamine agonist, 2021- 2031F |
6.1.4 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Decarboxylase inhibitors, 2021- 2031F |
6.1.5 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Cholinesterase Inhibitors, 2021- 2031F |
6.1.6 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Immunomodulators, 2021- 2031F |
6.1.7 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Philippines Neurodegenerative Drugs Market, By Indication |
6.2.1 Overview and Analysis |
6.2.2 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Parkinsons Disease, 2021- 2031F |
6.2.3 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Alzheimers Disease, 2021- 2031F |
6.2.4 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.2.5 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Philippines Neurodegenerative Drugs Market, By Distribution Channel |
6.3.1 Overview and Analysis |
6.3.2 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Hospital Pharmacies, 2021- 2031F |
6.3.3 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Online Providers, 2021- 2031F |
6.3.4 Philippines Neurodegenerative Drugs Market Revenues & Volume, By Drug Stores and Retail Pharmacies, 2021- 2031F |
7 Philippines Neurodegenerative Drugs Market Import-Export Trade Statistics |
7.1 Philippines Neurodegenerative Drugs Market Export to Major Countries |
7.2 Philippines Neurodegenerative Drugs Market Imports from Major Countries |
8 Philippines Neurodegenerative Drugs Market Key Performance Indicators |
9 Philippines Neurodegenerative Drugs Market - Opportunity Assessment |
9.1 Philippines Neurodegenerative Drugs Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.2 Philippines Neurodegenerative Drugs Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.3 Philippines Neurodegenerative Drugs Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Philippines Neurodegenerative Drugs Market - Competitive Landscape |
10.1 Philippines Neurodegenerative Drugs Market Revenue Share, By Companies, 2024 |
10.2 Philippines Neurodegenerative Drugs Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |